Loading stock data…
$9.52-0.09 (-0.89%)
Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific.
Certara, Inc. in the Healthcare sector is trading at $9.52 with a market capitalization of $1.1B. Wall Street consensus targets $8.90 (11 analysts), implying a -6.5% move over the next 12 months. The stock is currently 26% below its 52-week high of $12.94, remaining 32.2% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the distress zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $93.27M↓ | $106.92M↑ | $103.65M↓ | $104.62M↑ | $92.36M |
| Gross Profit | $58.15M↓ | $65.30M↑ | $64.48M↓ | $64.90M↑ | $58.07M |
| Operating Income | -$196,000↑ | -$4.30M↓ | $836,000↓ | $3.00M↓ | $7.67M |
| Net Income | -$55.27M↓ | -$8.76M↓ | -$5.89M↓ | $1.52M↑ | -$1.97M |
Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Mi...